


DESCRIPTION	
<b>Species Reactivity</b>	Mouse
<b>Specificity</b>	Detects mouse DCC in direct ELISAs and Western blots.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant mouse DCC Phe32-Asn1097 Accession # P70211
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

APPLICATIONS		
<b>Please Note:</b> Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.		
	Recommended Concentration	Sample
<b>Western Blot</b>	0.1 µg/mL	Recombinant Mouse DCC Fc Chimera (Catalog # 844-DC)
<b>Immunohistochemistry</b>	5-25 µg/mL	Immersion fixed paraffin-embedded sections of Mouse Embryo Developing Brain.
<b>Blockade of Receptor-ligand Interaction</b>	In a functional ELISA, 0.3-1.5 µg/mL of this antibody will block 50% of the binding of 50 ng/mL of Recombinant Chicken Netrin-2 (Catalog # 127-N2) to immobilized Recombinant Mouse DCC Fc Chimera (Catalog # 844-DC) coated at 2 µg/mL (100 µL/well). At 10 µg/mL, this antibody will block >90% of the binding.	

DATA	
<p><b>Immunohistochemistry</b></p> 	<p><b>Detection of DCC in Mouse Embryo Developing Brain.</b> DCC was detected in immersion fixed paraffin-embedded sections of Mouse Embryo Developing Brain using Goat Anti-Mouse DCC Antigen Affinity-purified Polyclonal Antibody (Catalog # AF844) at 15 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in neuronal processes. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.</p>

PREPARATION AND STORAGE	
<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

*Deleted in colorectal cancer (DCC)* was originally identified as a putative tumor suppressor gene that is lost in more than 70% of colorectal cancers. This gene has also been found to be deleted in several different kinds of cancers. *DCC* encodes a type I transmembrane glycoprotein that belongs to the immunoglobulin (Ig) superfamily. The extracellular domain is composed of four Ig-like domains and six fibronectin type III repeats. Two forms of the protein (the long and the short isoforms) are produced from the same gene by the use of alternative initiation sites. A third isoform that is produced by alternative splicing is expressed only in the embryo. The extracellular domain of mouse *DCC* shares 97% and 99% amino acid sequence identity with the human and rat *DCC* extracellular domains, respectively. In adults, *DCC* is highly expressed in the brain but is also expressed at very low levels in multiple tissues. In the embryo, high levels of expression are detected in the brain and neural tube. *DCC* has been shown to be a receptor for the netrins that are important for axon guidance. *DCC* has also been shown to induce apoptosis in the absence of ligand binding and to block apoptosis when engaged by netrin-1. *DCC* has been shown to be a caspase substrate. The pro-apoptotic effects of *DCC* were found to be dependent on the proteolytic cleavage of the unoccupied receptor by caspase. It is likely that *DCC* functions as a tumor-suppressor gene by inducing apoptosis in cells that are not exposed to netrins.

**References:**

1. Fearon, E.R. *et al.* (1990) *Science* **247**:49.
2. Keino-Masu, K. *et al.* (1996) *Cell* **87**:175.
3. Mehlen, P. *et al.* (1998) *Nature* **395**:801.
4. Culotti, J.G. and D.C. Merz (1998) *Current Opinion in Cell Biology* **10**:609.

**PRODUCT SPECIFIC NOTICES**

This product or the use of this product is covered by U.S. Patents owned by The Regents of the University of California. This product is for research use only and is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic, therapeutic or drug discovery purposes is prohibited. In order to obtain a license to use this product for such purposes, contact The Regents of the University of California.

U.S. Patent # 5,939,271, 6,277,585, and other U.S. and international patents pending.